HER2-positiv metastatisk brystkræft

Alan Celik; Tobias Berg; Ann Søeborg Knoop; Michael Andersson

HER2-positiv metastatisk brystkræft

Translated title of the contribution: Targeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly

Alan Celik
, Tobias Berg
, Ann Søeborg Knoop
, Michael Andersson

Abstract

Breast cancer is the most common type of cancer among women in Denmark. In 15% of the patients with metastatic breast cancer (mBC) an overexpression of the HER2 protein on the tumour cells, amplification of the HER2-gene or both are present. HER2-positive mBC is associated with poor disease prognosis. The discovery of HER2 led to the development of HER2-targeting monoclonal antibodies significantly improving survival for patients with HER2-positive mBC as summarised in this review. The future brings even more HER2-targeting drugs, which further can contribute to the palliative treatment of HER2-postive mBC patients.

Translated title of the contribution	Targeted treatment of HER2-positive metastatic breast cancer improves prognosis significantly
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	183
Issue number	26
Pages (from-to)	V12200938
ISSN	0041-5782
Publication status	Published - 28 Jun 2021
Externally published	Yes

Cite this

@article{df323ff3ba1f47078aa2b2daa6fa4758,

title = "HER2-positiv metastatisk brystkr{\ae}ft",

abstract = "Breast cancer is the most common type of cancer among women in Denmark. In 15\% of the patients with metastatic breast cancer (mBC) an overexpression of the HER2 protein on the tumour cells, amplification of the HER2-gene or both are present. HER2-positive mBC is associated with poor disease prognosis. The discovery of HER2 led to the development of HER2-targeting monoclonal antibodies significantly improving survival for patients with HER2-positive mBC as summarised in this review. The future brings even more HER2-targeting drugs, which further can contribute to the palliative treatment of HER2-postive mBC patients.",

keywords = "Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms/drug therapy, Female, Humans, Prognosis, Receptor, ErbB-2/therapeutic use",

author = "Alan Celik and Tobias Berg and Knoop, \{Ann S{\o}eborg\} and Michael Andersson",

year = "2021",

month = jun,

day = "28",

language = "Dansk",

volume = "183",

pages = "V12200938",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske L{\ae}geforening",

number = "26",

}

TY - JOUR

T1 - HER2-positiv metastatisk brystkræft

AU - Celik, Alan

AU - Berg, Tobias

AU - Knoop, Ann Søeborg

AU - Andersson, Michael

PY - 2021/6/28

Y1 - 2021/6/28

N2 - Breast cancer is the most common type of cancer among women in Denmark. In 15% of the patients with metastatic breast cancer (mBC) an overexpression of the HER2 protein on the tumour cells, amplification of the HER2-gene or both are present. HER2-positive mBC is associated with poor disease prognosis. The discovery of HER2 led to the development of HER2-targeting monoclonal antibodies significantly improving survival for patients with HER2-positive mBC as summarised in this review. The future brings even more HER2-targeting drugs, which further can contribute to the palliative treatment of HER2-postive mBC patients.

AB - Breast cancer is the most common type of cancer among women in Denmark. In 15% of the patients with metastatic breast cancer (mBC) an overexpression of the HER2 protein on the tumour cells, amplification of the HER2-gene or both are present. HER2-positive mBC is associated with poor disease prognosis. The discovery of HER2 led to the development of HER2-targeting monoclonal antibodies significantly improving survival for patients with HER2-positive mBC as summarised in this review. The future brings even more HER2-targeting drugs, which further can contribute to the palliative treatment of HER2-postive mBC patients.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms/drug therapy

KW - Female

KW - Humans

KW - Prognosis

KW - Receptor, ErbB-2/therapeutic use

UR - https://www.scopus.com/pages/publications/85110921529

M3 - Review

C2 - 34219638

SN - 0041-5782

VL - 183

SP - V12200938

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 26

ER -

HER2-positiv metastatisk brystkræft

Abstract

Other files and links

Fingerprint

Cite this